Drug Discovery
A Casebook and Analysis

By

Robert A. Maxwell
The Wellcome Research Laboratories
Research Triangle Park, North Carolina

and

Shohreh B. Eckhardt
University of Vermont College of Medicine,
Burlington, Vermont

Humana Press • Clifton, New Jersey
## Contents

Preface ............................................................................................................................... v
Acknowledgments ............................................................................................................. vii
Introduction ...................................................................................................................... xvii
Definitions for Table 1 ...................................................................................................... xxiii

**Cardiovascular and Renal Group**  
(Including Renal Transplantation)

### Propranolol
- I. Propranolol as an Innovative Therapeutic Agent ..........3
- II. The Scientific Departure Leading to Propranolol:  
  Dichloroisoproterenol (DCI) .................................................. 6
- III. Comments on Events Leading to Propranolol ..........11
- IV. Developments Subsequent to Propranolol ...............14
  References .............................................................................. 15

### Captopril
- I. Captopril as an Innovative Therapeutic Agent ..........19
- II. The Scientific Departure Leading to Captopril:  
  Teprotide .............................................................................. 22
- III. Comments on Events Leading to Captopril ..........26
- IV. Developments Subsequent to Captopril ...............28
  References .............................................................................. 29

### Calcium Antagonists: Verapamil, Nifedipine, Diltiazem
- I. Calcium Antagonists—Verapamil, Nifedipine,  
  Diltiazem—as Innovative Therapeutic Agents ..........35
- II. The Scientific Work Leading to Verapamil,  
  Nifedipine, and Diltiazem .................................................. 40
- III. Comments on Events Leading to Ca Antagonists ....43
- IV. Developments Subsequent to Verapamil,  
  Nifedipine, and Diltiazem .................................................. 45
  References .............................................................................. 47
Chlorothiazide
I. Chlorothiazide as an Innovative Therapeutic Agent ... 53
II. The Scientific Departure Leading to Chlorothiazide:
   Sulfanilamide ........................................................................................................... 55
III. Comments on Events Leading to Chlorothiazide ............. 60
IV. Developments Subsequent to Chlorothiazide ................. 62
    References ............................................................................................................... 63

Furosemide
I. Furosemide as an Innovative Therapeutic Agent ............ 67
II. The Scientific Work Leading to Furosemide ................. 70
III. Comments on Events Leading to Furosemide ............. 73
IV. Developments Subsequent to Furosemide .................... 74
    References ............................................................................................................... 75

Azathioprine
I. Azathioprine as an Innovative Therapeutic Agent ............ 79
II. The Scientific Departure Leading to Azathioprine:
    6-Mercaptopurine ............................................................................................... 82
III. Comments on Events Leading to Azathioprine ............. 87
IV. Developments Subsequent to Azathioprine ................. 88
    References ............................................................................................................... 89

Cyclosporine
I. Cyclosporine as an Innovative Therapeutic Agent ............ 95
II. The Scientific Work Leading to Cyclosporine ................. 99
III. Comments on Events Leading to Cyclosporine ............. 103
IV. Developments Subsequent to Cyclosporine .................... 104
    References ............................................................................................................... 105

**Psychiatry Group**

Chlorpromazine
I. Chlorpromazine as an Innovative
   Therapeutic Agent ............................................................................................... 111
II. The Scientific Departure Leading to Chlorpromazine:
    Promethazine ....................................................................................................... 112
Contents

III. Comments on Events Leading to Chlorpromazine .... 117
IV. Developments Subsequent to Chlorpromazine .......... 119
References ..................................................................... 120

Haloperidol
I. Haloperidol as an Innovative Therapeutic Agent ..... 123
II. The Scientific Work Leading to Haloperidol .......... 125
III. Comments on Events Leading to Haloperidol ...... 128
IV. Developments Subsequent to Haloperidol .......... 129
References ..................................................................... 130

Imipramine
I. Imipramine as an Innovative Therapeutic Agent ..... 133
II. The Scientific Work Leading to Imipramine .......... 134
III. Comments on Events Leading to Imipramine ...... 138
IV. Developments Subsequent to Imipramine .......... 139
References ..................................................................... 140

Iproniazid
I. Monoamine Oxidase Inhibitors (MAOIs)
   as Innovative Therapeutic Agents ......................... 143
II. The Scientific Work Leading to Iproniazid .......... 144
III. Comments on Events Leading to Iproniazid ...... 148
IV. Developments Subsequent to Iproniazid .......... 150
References ..................................................................... 152

Lithium
I. Lithium (Li+) as an Innovative Therapeutic Agent .... 155
II. The Scientific Work Leading to Lithium
   as an Antimanic Agent .............................................. 157
III. Comments on Events Leading to Lithium .......... 160
IV. Developments Subsequent to Lithium .......... 161
References ..................................................................... 162

Chlordiazepoxide and Diazepam
I. Chlordiazepoxide and Diazepam
   as Innovative Therapeutic Agents ......................... 165
II. The Scientific Work Leading to Chlordiazepoxide
   and Diazepam .......................................................... 168
III. Comments on Events Leading to Chlordiazepoxide
and Diazepam ................................................................. 170
IV. Developments Subsequent to Chlordiazepoxide
and Diazepam ................................................................. 172
References ........................................................................ 173

Neurology Group

L-Dopa
   I. L-Dopa as an Innovative Therapeutic Agent ............ 179
   II. The Scientific Work Leading to L-Dopa
       as a Treatment for Parkinsonism ............................. 181
   III. Comments on Events Leading to L-Dopa ............... 186
   IV. Developments Subsequent to L-Dopa ...................... 187
       References ................................................................. 188

Carbamazepine
   I. Carbamazepine as an Innovative Therapeutic Agent ........................................... 193
   II. The Scientific Work Leading to Carbamazepine ......... 198
   III. Comments on Events Leading to Carbamazepine ...... 200
   IV. Developments Subsequent to Carbamazepine ......... 202
       References ................................................................. 202

Rheumatology Group

Indomethacin
   I. Indomethacin as an Innovative Therapeutic Agent ... 209
   II. The Scientific Work Leading to Indomethacin .......... 214
   III. Comments on Events Leading to Indomethacin ...... 215
   IV. Developments Subsequent to Indomethacin .......... 216
       References ................................................................. 217

D-Penicillamine
   I. D-Penicillamine as an Innovative Therapeutic Agent ........................................... 221
   II. The Scientific Work Leading to D-Penicillamine
       as an Antirheumatic Agent ........................................ 225
Contents

III. Comments on Events Leading to d-Penicillamine ..... 229
IV. Developments Subsequent to d-Penicillamine .......... 229
References ................................................................................. 230

Hydroxychloroquine

I. Hydroxychloroquine as an Innovative Therapeutic Agent ............................................. 235
II. The Scientific Departure Leading to the Use of Hydroxychloroquine in Rheumatoid Arthritis: Quinacrine ................................................................. 238
III. Comments on Events Leading to the Use of Hydroxychloroquine in Rheumatoid Arthritis... 243
IV. Developments Subsequent to Hydroxychloroquine .. 244
References ................................................................................. 245

Methotrexate

I. Methotrexate as an Innovative Therapeutic Agent .... 249
II. The Scientific Departure Leading to Methotrexate: Aminopterin ............................................. 253
III. Comments on Events Leading to Methotrexate ...... 256
IV. Developments Subsequent to Methotrexate ........ 258
References ................................................................................. 259

Cyclophosphamide

I. Cyclophosphamide as an Innovative Therapeutic Agent ............................................. 265
II. The Scientific Departure Leading to Cyclophosphamide: Mechlorethamine (Nitrogen Mustard) ................................................................. 269
III. Comments on Events Leading to Cyclophosphamide ............................................. 273
IV. Developments Subsequent to Cyclophosphamide .... 275
References ................................................................................. 275

Anesthesiology Group

Succinylcholine

I. Succinylcholine as an Innovative Therapeutic Agent ............................................. 283
II. The Scientific Departure Leading to Succinylcholine: Decamethonium .......................................................... 287
III. Comments on Events Leading to Succinylcholine ...... 292
IV. Developments Subsequent to Succinylcholine .......... 292
References ...................................................................... 294

Halothane
I. Halothane as an Innovative Therapeutic Agent .......... 297
II. The Scientific Work Leading to Halothane ............... 300
III. Comments on Events Leading to Halothane .......... 302
IV. Developments Subsequent to Halothane ............... 303
References ...................................................................... 304

Fentanyl
I. Fentanyl as an Innovative Therapeutic Agent .......... 307
II. The Scientific Work Leading to Fentanyl ............... 310
III. Comments on Events Leading to Fentanyl .......... 314
IV. Developments Subsequent to Fentanyl ............... 315
References ...................................................................... 316

Naloxone
I. Naloxone as an Innovative Therapeutic Agent .......... 319
II. The Scientific Departure Leading to Naloxone:
    Nalorphine .................................................................. 321
III. Comments on Events Leading to Naloxone .......... 325
IV. Developments Subsequent to Naloxone .............. 325
References ...................................................................... 328

Pulmonary Group

Albuterol
I. Albuterol as an Innovative Therapeutic Agent .......... 333
II. The Scientific Work Leading to Albuterol .......... 336
III. Comments on Events Leading to Albuterol .......... 342
IV. Developments Subsequent to Albuterol .............. 344
References ...................................................................... 345

Beclomethasone Dipropionate
I. Beclomethasone Dipropionate
    as an Innovative Therapeutic Agent ................. 349
II. The Scientific Work Leading to the Use of Inhaled Beclomethasone Dipropionate in Asthma ................................................................. 353
III. Comments on Events Leading to Beclomethasone Dipropionate ................................................................. 358
IV. Developments Subsequent to Beclomethasone Dipropionate ................................................................. 359
References ........................................................................................................... 359

Gastrointestinal Group

Cimetidine
I. Cimetidine as an Innovative Therapeutic Agent ............ 365
II. The Scientific Departure Leading to Cimetidine:
    Burimamide ................................................................................................. 367
III. Comments on Events Leading to Cimetidine .......... 371
IV. Developments Subsequent to Cimetidine .................... 373
    References ..................................................................................................... 373

Chenodeoxycholic Acid and Ursodeoxycholic Acid
I. Chenodeoxycholic Acid and Ursodeoxycholic Acid
    as Innovative Therapeutic Agents ............................................................. 377
II. The Scientific Work Leading to Chenodeoxycholic Acid
    and Ursodeoxycholic Acid as Treatments for Gallstones ...................... 380
III. Comments on Events Leading to Chenodeoxycholic
    Acid and Ursodeoxycholic Acid ............................................................... 385
IV. Developments Subsequent to Chenodeoxycholic
    Acid and Ursodeoxycholic Acid ............................................................... 386
    References ..................................................................................................... 386

Analysis and Interpretation

Summaries of the Analyses of Table 1 ................................. 391
IA. The Initiation of the 30 Lines of Research ...................... 392
IB. The Total Number of Entries for the 30 Lines of Research ................................. 393
II. The 32 Innovative Drugs ................................................................. 393
III. The Innovative Drugs Taken as Groups .....................396

Interpretation ........................................................................................................399
   I. Actions and Interactions of the Various Research Institutions .....................400
   II. Routes to Discovery .......................................................................................406
   III. Attitudes .....................................................................................................412
        References ......................................................................................................415

Appendix: Analyses of Tables
   I. Analysis of 30 Lines of Research .................................................................417
   II. Analysis of 32 Innovative Drugs .................................................................421
   III. Analysis of the Innovative Drugs Taken as Groups ...425

Index .....................................................................................................................429